A
Allergan
Allergan agreed to pay nearly $30 million to resolve claims it used anti-competitive tactics to raise Restasis prices.
ClosedSelected statesClaim status: Closed on August 11, 2022Payout: VariesNo longer claimable
About this settlement
Alleged antitrust violations involving price increases for Restasis eye drops.
This settlement resolves claims that Allergan used anti-competitive tactics to raise prices on Restasis eye drops. Eligible consumers and third-party payors who purchased Restasis in specified states between May 2015 and July 2021 may receive compensation.
Who qualifies
- Consumers who purchased Restasis eye drops between May 1, 2015 and July 31, 2021 in eligible states.
- Third-party payors such as employers and insurers who purchased Restasis in eligible states during the same period.
Varies
Claim status: Closed on August 11, 2022